Skip to main content
TCRG
OTC Life Sciences

Cannaisseur Q3 10-Q: $20 Cash, Going Concern Doubt, New Sense Asset Deal

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.75
Mkt Cap
--
52W Low
$0.005
52W High
$2.99
52W Position
Off High info
75% below high
Rel. Volume
Market data snapshot near publication time

Summary

Cannaisseur finished Q3 2026 with $20 of cash and $430,335 of liabilities, repeating its going-concern warning, while signing a new all-preferred-stock asset deal with Sense that has not closed.


Key Events · Earnings and Guidance · TCRG

  • Going Concern Doubt Repeated

    Management concluded there is substantial doubt about the company's ability to continue as a going concern within one year, citing a $3,771,468 accumulated deficit and a $406,031 working capital deficit.

  • Cash Down to $20

    Cash stood at $20 at September 30, 2026 versus $22 at December 31, 2025, while total liabilities rose to $430,335 from $235,431, driven by accounts payable and accrued expenses of $387,066.

  • Loss Narrows on Lower Stock Comp

    The nine-month net loss was $282,986 versus $1,706,736 a year earlier, mainly because share-based compensation fell to $0 from $1,292,962.

  • New Sense Asset Deal Signed

    On October 26, 2026 the company agreed to buy real property, equipment and fixtures from Sense Technologies and Sense Natural Products for 500,000 Class B Preferred Shares; the deal has not closed and no consideration has been exchanged.


Analysis · TCRG · Life Sciences

With $20 of cash at September 30, 2026 against $430,335 of liabilities and a $406,031 working capital deficit, management again flags substantial doubt about the company's ability to continue as a going concern within one year. The only funding in the first nine months came from $87,962 of related-party capital contributions — no equity was sold and no third-party financing was raised. Against that backdrop, the company signed a new October 26, 2026 asset purchase agreement with Sense Technologies and Sense Natural Products for 500,000 Class B Preferred Shares, replacing the August 2025 deal that was terminated without ever closing. Until that closes and cash arrives, the balance sheet has essentially no cushion.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TCRG was trading at $0.75 on OTC in the Life Sciences sector. The 52-week trading range was $0.00 to $2.99. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TCRG - Latest Insights

TCRG
Aug 12, 2026, 11:40 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.060
Real-time Price: $0.750 info
Change: +$0.690 (+1,150%) info
Market Cap: N/A info
TCRG
May 08, 2026, 5:32 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.750
Real-time Price: $0.750 info
Change: $0 (0%) info
Market Cap: N/A info
TCRG
Mar 23, 2026, 1:13 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $0.0136
Real-time Price: $0.750 info
Change: +$0.7364 (+5,415%) info
Market Cap: N/A info